Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Update Il y a 4 ans
Reference: NCT01048099

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2 overexpression/activation by the PRO Onc Assay.


Inclusion criteria

  • Breast Cancer

Links